DiaMedica Therapeutics

DMAC · Nasdaq · United States

Share price · DMAC

$8.59+1.98 (+29.95%) 3M

close as of 2026-11-18 · 24h delayed · vol 207K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when DMAC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026-16.1%
  2. 3 Nov 2026+7.6%

    Nothing announced by DMAC that day or the session before.

  3. 28 Oct 2026+13.0%
  4. 20 Oct 2026+10.2%
  5. 21 Sep 2026+6.0%

    Nothing announced by DMAC that day or the session before.

  6. 1 Jul 2026+5.7%
  7. 29 Jun 2026+10.2%

    Nothing announced by DMAC that day or the session before.

  8. 23 Jun 2026+6.6%
  9. 26 May 2026+6.9%

    Nothing announced by DMAC that day or the session before.

  10. 8 Apr 2026-5.5%

    Nothing announced by DMAC that day or the session before.

Share of unusual movement by asset

For each asset, the share of DMAC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Rinvecalinase alfa
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—87%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2/3
Tissue kallikrein-1 (KLK1)Protein / enzyme therapeutic
Acute Ischemic Stroke

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Rinvecalinase alfaPhase 2/3Acute Stroke, Ischemic Stroke, Stroke
Est. primary completion 2026-12 · NCT05065216 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$9.2M$6.8M+ $28M short-term inv.$11M-$8.8M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$8.2M$5.1M+ $38M short-term inv.$10M-$8.1M operating cash flowreport ↗
2026-Q1—$8.0M$4.9M+ $46M short-term inv.$10M-$9.1M operating cash flowreport ↗
2025-Q3—$6.4M$3.3M+ $52M short-term inv.$8.6M-$6.5M operating cash flowreport ↗
2025-Q2—$5.8M$4.1M+ $26M short-term inv.$7.7M-$7.6M operating cash flowreport ↗
2025-Q1—$5.7M$2.6M+ $34M short-term inv.$7.7M-$7.2M operating cash flowreport ↗
2024-Q3—$5.0M$4.1M+ $46M short-term inv.$6.3M-$4.5M operating cash flowreport ↗
2024-Q2—$3.9M$14M+ $40M short-term inv.$5.1M-$4.5M operating cash flowreport ↗
2024-Q1—$3.7M$2.1M+ $44M short-term inv.$5.2M-$6.7M operating cash flowreport ↗
2023-Q3—$3.3M$2.2M+ $44M short-term inv.$4.5M-$4.8M operating cash flowreport ↗
2023-Q2—$2.5M$5.8M+ $35M short-term inv.$4.5M-$5.0M operating cash flowreport ↗
2023-Q1—$3.6M$2.1M+ $27M short-term inv.$5.3M-$5.1M operating cash flowreport ↗
2022-Q3—$1.6M$2.8M+ $33M short-term inv.$3.1M-$2.4M operating cash flowreport ↗
2022-Q2—$2.0M$3.1M+ $35M short-term inv.$3.4M-$2.5M operating cash flowreport ↗
2022-Q1—$2.0M$3.0M+ $38M short-term inv.$3.5M-$3.9M operating cash flowreport ↗
2021-Q3—$2.3M$16M+ $32M short-term inv.$3.5M-$3.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$25M$16M+ $44M short-term inv.$8.2M-$29M operating cash flowreport ↗

For fiscal year 2025, DiaMedica Therapeutics reported no disclosed revenue. R&D spend was $24.61M, up 29.1% YoY from $19.06M, with cash and equivalents of $15.65M. The company reported a net loss of $32.77M and a quarterly net burn of $32.77M.

DiaMedica continued clinical development of DM199 across its preeclampsia/fetal growth restriction and acute ischemic stroke programs. Interim results from Part 1a of the investigator-sponsored Phase 2 PE study indicated DM199 was safe and well-tolerated with no placental transfer, and preparations were underway for Part 1b. The company also held a pre-IND meeting with the FDA for its planned early-onset PE Phase 2 study, where the FDA requested an additional ePPND study; preliminary rabbit results showed an antibody response to DM199, leading the company to evaluate alternative models. For AIS, the Phase 2/3 ReMEDy2 trial remains designed to enroll approximately 300 participants at up to 100 global sites, with an interim analysis after 200 participants and a possible final sample size up to 728. In March 2026, Health Canada approved initiation of a Phase 2 study in early-onset preeclampsia, with a UK clinical trial application anticipated in the second quarter of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$19M$3.0M+ $41M short-term inv.$6.1M-$22M operating cash flowreport ↗
2023-FY—$13M$4.5M+ $48M short-term inv.$4.8M-$19M operating cash flowreport ↗
2022-FY—$7.8M$4.7M+ $29M short-term inv.$3.4M-$12M operating cash flowreport ↗
2021-FY—$8.8M$4.7M+ $40M short-term inv.$3.4M-$12M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($2.5M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-10Pauls Dietrich John · director, President & CEOAward / grant60,200——Form 4
2026-06-01Krop Julie · Chief Medical OfficerAward / grant (derivative)67,500——Form 4
2026-06-01Kellen Scott · CFO & SecretaryAward / grant (derivative)162,000——Form 4
2026-06-01Pauls Dietrich John · director, President & CEOAward / grant (derivative)380,000——Form 4
2026-06-01Parsons James T. · directorAward / grant (derivative)51,189——Form 4
2026-06-01Semba Charles Pauling · directorAward / grant (derivative)40,412——Form 4
2026-06-01Lewis Tanya · directorAward / grant (derivative)40,412——Form 4
2026-06-01O'Connor Daniel J. · directorAward / grant (derivative)40,412——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 98 reporting institutions held 11.8M shares ($79.0M, 21.8% of shares outstanding).

#InstitutionSharesValue
1COOPERMAN LEON G2,020,000$13.7M
2BlackRock, Inc.1,856,187$12.6M
3MILLENNIUM MANAGEMENT LLC935,592$6.3M
4PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE875,000$5.9M
5GEODE CAPITAL MANAGEMENT, LLC780,516$5.3M
6STATE STREET CORP644,211$4.4M
7FIRST MANHATTAN CO. LLC.455,000$3.1M
8Bleichroeder LP382,317$2.6M
9NORTHERN TRUST CORP338,526$2.3M
10VANGUARD CAPITAL MANAGEMENT LLC333,456$2.3M
11OSAIC HOLDINGS, INC.319,675$2.2M
12LPL Financial LLC226,050$1.5M
13VANGUARD PORTFOLIO MANAGEMENT LLC203,459$1.4M
14VANGUARD FIDUCIARY TRUST CO187,724$1.3M
15CITADEL ADVISORS LLC145,724$987K